Article | Number (M/F)1 | C/R/R-S2 | Age Mean ± SD3/Median (range) | ST4 | Cut-off | Rate(+)5 | Follow up Mean ± SD/Median (range) | OM6 | Surgery | MA7 |
---|---|---|---|---|---|---|---|---|---|---|
Sotelo 2014 [24] | 472(254/218) | 425/47/0 | Median:66(31–87) | Baseline | ≥1/7.5 ml | 166/472 | Median:40(NR8) | OS9; PFS10 | YES | NO |
 | 472(254/218) | 425/47/0 | Median:66(31–87) | Baseline | ≥2/7.5 ml | 93/472 | Median:40(NR) | OS; PFS | YES | NO |
 | 472(254/218) | 425/47/0 | Median:66(31–87) | Baseline | ≥3/7.5 ml | 57/472 | Median:40(NR) | OS; PFS | YES | NO |
 | 472(254/218) | 425/47/0 | Median:66(31–87) | Baseline | ≥5/7.5 ml | 34/472 | Median:40(NR) | OS; PFS | YES | NO |
Seeberg 2014 [25] | 194(105/89) | 124/70 | Median:65(31–93) | Baseline | ≥1/7.5 ml | 37/189 | Median:22.5(1–61) | OS; PFS | 153YES | NO |
 | 194(105/89) | 124/70 | Median:65(31–93) | Baseline | ≥2/7.5 ml | 26/189 | Median:22.5(1–61) | OS; PFS | 153YES | YES |
 | 194(105/89) | 124/70 | Median:65(31–93) | Baseline | ≥3/7.5 ml | 17/189 | Median:22.5(1–61) | OS; PFS | 153YES | NO |
Gazzaniga 2013 [26] | 119(68/51) | NR | Median:64(29–84) | Baseline | ≥1/7.5 ml | 44/119 | Median:12(1–26) | PFS | NR | YES |
 | 119(68/51) | NR | Median:64(29–84) | Baseline | ≥3/7.5 ml | 24/119 | Median:12(1–26) | PFS | NR | YES |
Aggarwal 2013 [27] | Baseline:209(NR) | NR | Mean:63.0 ± 12.6 Median: 64 (22–92) | Baseline | ≥3/7.5 ml | 62/209 | median: NR(0.2-39.1) | OS | NR | YES |
 | 3-5 W:115(NR) 6-12 W:134(NR) | NR | NR | During-treatment: 3-5 W,6-12 W11 | ≥3/7.5 ml | 3-5 W: 17/115; 6-12 W: 10/134 | NR | OS | NR | YES |
Kuboki 2013 [14] | 63(34/29) | 41/22/0 | Median: 61(33–81) | Baseline | ≥3/7.5 ml | 19/63 | Median:8.7(NR) | OS; PFS | NR | YES |
Deneve 2013 [13] | 69(43/26) | 66/8/1 | Median: 75(38–95) | Baseline | ≥1/7.5 ml | 20/69 | Mean:31 ± NR Median:36 (0–52) | NR | YES | NO |
Sastre 2012 [28] | Baseline:180(118/62) | 40/121/19 | Median: 65(40–82) | Baseline | ≥3/7.5 ml | 85/180 | NR | OS; PFS | 123YES | YES |
 | Cycle3:147(NR) | NR | NR | Cycle3 | ≥3/7.5 ml | 23/147 | NR | OS; PFS | 123YES | NO |
Sato 2012 [29] | 25(NR) | NR | NR | Baseline | ≥3/7.5 ml | 14/25 | NR | OS | M1:NO12 | NO |
 | 25(NR) | NR | NR | Baseline | ≥1/7.5 ml | 18/25 | NR | OS | M1:NO | NO |
Papavasiliou 2010 [30] | 20(13/7) | NR | Median: 54 (41–81) | Baseline During-treatment | ≥3/7.5 ml | Pre:2/20 intra: 10/20; post: 1/18 | Median:11.5 (5–25) | OS; PFS | YES | NO |
Tol 2010 [31] | 467 (284/183) | 225/122/ 120 | Median: 63(27–83) | Baseline | ≥3/7.5 ml | Baseline: 129/451 | Median: 16.8(NR) | OS; PFS | NR | YES |
 | 1-2 W: 368(NR) 3-5 W:320(NR) 6-12 W:336(NR) 13-20 W: 254(NR) | NR | Median: 63(27–83) | During-treatment: 1-2/3-5/6-12/13-20 W | ≥3/7.5 ml | 1-2 W: 21/368; 3-5 W: 17/320; 6-12 W: 18/336; 13-20 W: 16/254 | NR | OS; PFS | NR | YES |
Hiraiwa 2008 [15] | 40(NR) | NR | NR | Baseline + During-treatment | ≥2/7.5 ml | 14/40 | NR | OS | YES | YES |